Who are the young bio­phar­ma lead­ers shap­ing the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

We were in the home­stretch for our an­nu­al 20 un­der 40 project when the pan­dem­ic hit the US. On March 8, I can­celed my train tick­ets to Boston to meet with nom­i­nees Ja­son Kel­ly at Gink­go and David Cheng. The next day was the first warm day in New York City, and the streets and parks were lit­tered with jog­gers and fam­i­lies out chat­ting in shrill, vol­u­ble tones af­ter three months cooped in the cold. I spoke ami­ably on the phone with Otel­lo Stam­pac­chia about how biotech was adapt­ing and about his fam­i­ly in Italy, the cri­sis there and the cri­sis com­ing. The WHO de­clared a pan­dem­ic two days lat­er. Soon, no one was out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.